News

July 26, 2017July 26, 2017

Pulmonary Fibrosis Therapy SM04646 Receives FDA Orphan Drug Designation

The U.S. Food and Drug Administration has granted orphan drug status to SM04646, San Diego-based Samumed‘s treatment for idiopathic pulmonary fibrosis. SM04646, which is delivered in a mist, could be approved as a ... Read more

July 25, 2017July 25, 2017

ZappRx Implements Specialty Medication Prescribing Platform at 2 Pulmonary Medical Centers

Cystic Fibrosis, Idiopathic Pulmonary Fibrosis, News, Pulmonary Hypertension

Harbor-UCLA Medical Center in Torrance, California, and Phoenix-based Arizona Pulmonary Specialists — the largest U.S. private practice treating pulmonary hypertension — now offer a digital platform designed by ZappRx to facilitate the complex ... Read more

July 24, 2017July 24, 2017

Real-world Safety of Ofev and Esbriet Matches Trial Reports, Despite Office Patients Older, Sicker

Idiopathic Pulmonary Fibrosis, News

Patients treated with Ofev (nintedanib) or Esbriet (pirfenidone) for pulmonary fibrosis in a real-world setting have similar rates of side effects as those reported in clinical trials testing the drugs, despite ... Read more

July 21, 2017July 21, 2017

Maternal Exposure to Environmental Pollution Increases Asthma Risk in Offspring for 3 Generations, Study Finds

Asthma, News

Exposure to environmental pollutants during pregnancy may boost the risk of asthma in offspring for up to three consecutive generations, a study found. The mouse study, “Transgenerational transmission of asthma risk after exposure ... Read more

July 20, 2017July 20, 2017

Samumed Completes Phase 1 Study of Potential IPF Treatment with Positive Results

Idiopathic Pulmonary Fibrosis, News

Samumed has successfully completed a Phase 1 clinical trial in healthy individuals to evaluating a potential therapy — a nebulized inhalation solution called SM04646 — that treats idiopathic pulmonary fibrosis (IPF). The positive ... Read more

July 19, 2017July 19, 2017

Sunovion Divests US Market Rights on Asthma and Allergic Rhinitis Therapies to Focus on COPD

Asthma, COPD, News

Sunovion Pharmaceuticals has entered an agreement with Covis Pharma to divest the U.S. market rights of a series of products based on ciclesonides approved for the treatment of asthma and allergic rhinitis. Ciclesonides are in ... Read more

July 18, 2017July 18, 2017

Mount Sinai, Theragene Collaborate to Develop New Gene Therapy for Pulmonary Hypertension

News, Pulmonary Hypertension

Researchers from New York’s Mount Sinai have partnered with Theragene Pharmaceuticals to further develop a new airway-delivered gene therapy for pulmonary hypertension (PH). After showing promising results in animal studies, this new therapy will advance to clinical trials, ... Read more

July 17, 2017July 17, 2017

Esbriet, Ofev Remain the Most Reliable Therapies for Idiopathic Pulmonary Fibrosis, Comparison Study Shows

Idiopathic Pulmonary Fibrosis, News

The first two approved therapies for idiopathic pulmonary fibrosis (IPF), Genentech’s Esbriet (pirfenidone) and Boehringer Ingelheim’s Ofev (nintedanib), are still the most reliable treatments among several approved and experimental therapies, according to a ... Read more

July 14, 2017July 14, 2017

Researchers Identify a Type of Immune Cells that Contribute to Lung Fibrosis

Idiopathic Pulmonary Fibrosis, News

Certain immune cells, called monocyte-derived alveolar macrophages, may contribute to lung inflammation and fibrosis, according to the results of a new study. Researchers believe that therapies targeting these monocyte-derived macrophages may ... Read more

July 12, 2017July 12, 2017

High Sugar Intake While Pregnant May Increase Child’s Risk of Developing Allergic Asthma, Study Finds

Asthma, News

Women who consume a large amount of sugar when they’re pregnant may find their children at an increased risk for allergy and allergic asthma, according to researchers from Queen Mary University ... Read more